Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renamezin for Sarcopenia Prevention in Pre-dialysis CKD
NCT03788252Phase 4Completed
- Sponsor
- CHA Gumi Medical Center
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Renamezin in Sarcopenia, sponsored by CHA Gumi Medical Center. Started Nov 2018; status: completed.
02
Drugs
Renamezin
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT03788252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788252.